Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

>)

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics for major unmet medical needs. Aegera has three programs in clinical development. In addition to AEG33773, Aegera is developing

    - AEG35156 targets the key anti-apoptotic protein XIAP, and is in
      multiple randomized Phase II clinical trials;
    - HGS1029(AEG40826) is a small molecule pan-IAP inhibitor in Phase 1
      development. It has demonstrated very promising preclinical activity
      and is partnered with Human Genome Sciences, Inc. (Nasdaq:  HGSI) for o
      ncology in all countries except Japan.

'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/bvxxkf/cytogenetics ) has announced the addition ... - Technologies, Markets and Companies" to ... cytogenetics includes several technologies besides fluorescence in ... and multicolor FISH. Molecular cytogenetics includes application ...
(Date:9/2/2015)... ... September 02, 2015 , ... Drug ... plant-derived compounds. BCC Research reveals in its new report that the U.S. ... defines the category and generates the most market demand. , BCC Research ...
(Date:9/2/2015)... -- Australian prostate cancer technology company Minomic International Ltd ... ,outstanding, science that uses its patented antibody. ... prostate cancer diagnostic test known as MiCheck® next year, ... the peer-reviewed Australian Museum Eureka Science Prize for ... prize is awarded for ground breaking research that has ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3
... Inc., (TSX:,ARI), a biotechnology company discovering and developing ... five abstracts have been,selected for presentation at the ... from April 12-16, 2008 in San Diego, California.,The ... findings,about its CD44, TROP-2, CD59, and CD9 antibody ...
... Time to Brazil ... and ... of the Sanofi-aventis Group, announced today that six,million doses of Stamaril(TM)(1) ... the yellow fever epidemic in Latin,America., Brazil received four million ...
... - $2 M to ProMetic over the next 12 months - $30 M ... ... in-licensed ProMetic,s yield improving technology, - Incorporation of ProMetic,s prion reduction technology ... manufacturing process, ...
Cached Biology Technology:ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting 2ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting 3Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America 2Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America 3ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 2ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 3ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 4
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Arabia Biomedical Sensors market is estimated at $0.23 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015 ... on consumers that are active and healthy. However, ... in the hospital environment to help improve diagnostic ... a video from the Wearable Technologies Conference ... discussed new applications for wearables in healthcare.    ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... A team of scientists from The Scripps Research ... the deadliest antibiotic-resistant bacteria. The compound could one day ... highly resistant bacterial infections. The results were published ... of the American Chemical Society . "[These results] ...
... AURORA, Colo. (Aug. 24, 2011) A scientist investigating why ... coordination has found that key eye reflexes are substantially altered. ... researcher Alberto Costa, MD, Ph.D., could lead to new tools ... at improving quality of life for those with this genetic ...
... The delivery system for an important class of proteins ... mere three components, according to a new study. ... percent of the membrane proteins in a cell, are known ... membrane after construction. New research from the University of Chicago ...
Cached Biology News:Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 2Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 3Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 4Researcher finds altered cerebella in those with Down syndrome 2Three-part handoff delivers proteins to membrane surface 2Three-part handoff delivers proteins to membrane surface 3
... PHD2000 syringe pump series combines Harvard Apparatuss best ... and a wide range of configuration options. A ... dimensions of syringes from all the major manufacturers. ... all the pertinent information from across the lab. ...
... is a new product number, created to ... no availability yet, please order under the ... service for assistance. Feature: tissue-culture ... area 21 cm 2 D ...
... Time-resolved microscopy is the ultimate tool ... subcellular structures. Its applications previously have been ... because microscope optics do not transmit in ... leader in fluorescence spectroscopy, introduces a filter-based ...
... High-throughput protein crystallography involves using many ... Screening (HTS). The liquid handling requirements are ... volume: traditional crystallography plates have 24 or ... of microliters. For higher throughput, the number ...
Biology Products: